As cannabis science continues to build substantiation, many companies are developing products that attempt to apply classic pharmaceutical principles to cannabis products. They figure that by separating a specific cannabinoid from the rest of the hemp plant, they can target treatment more accurately. Sounds logical, right? But in 2015, a team of researchers out of Israel published a watershed report that turned that logic upside down.
The report indicates that isolated cannabinoids yield bell-curve results in symptom management—meaning that after a specific dosage of cannbinoids, the benefits rapidly level off. But when CBD, a naturally occuring constituent of hemp, is combined with other cannabinoids and terpenes (all naturally occurring in hemp) the results are drastically different. The whole-plant product extract yields dose-dependent results—meaning the more whole-plant product administered, the greater the response and condition management effects. These researchers now also believe that phytopharmaceuticals, or formulations derived from whole plant extracts, have fewer adverse effects and lower overall toxicity than formulations composed of isolated plant components.